Pharmaceutical Executive-12-01-2009

China's explosive growth in R&D is putting the natiion on its way to becoming the world's second-largest market by 2020

As the old orthodoxy shatters, pharma must stand firm or leave the field.

Marketers will need to address not only the benefits of the therapy but also the benefits of a diagnostic assay.

They already dominate the pharmaceutical market, and now generics are poised to move into biologics and complex dosage forms.

Process-driven managed-care rebating programs can drive profitability

Our sixth annual pipeline report details 44 drugs that industry will be talking about in 2010.

The fight against cancer may be the litmus test for how regulation and private investment work together to address the disease burden.